The diagnosis of urinary tract infection in young children (DUTY) study clinical rule: economic evaluation by Hollingworth, William et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 5 5 6 – 5 6 61098-3015$36.00 – s
Published by Elsevie
http://dx.doi.org/10.
E-mail: william.h
* Address correspo
Whatley Road, Bristjournal homepage: www.elsevier .com/ locate / jva lThe Diagnosis of Urinary Tract Infection in Young Children
(DUTY) Study Clinical Rule: Economic Evaluation
William Hollingworth, PhD1,*, John Busby, MSc1, Christopher C. Butler, FRCGP2, Kathryn O’Brien, PhD3,
Jonathan A.C. Sterne, PhD1, Kerenza Hood, PhD4, Paul Little, FRCGP5, Michael Lawton, MPhil1,
Kate Birnie, PhD1, Emma Thomas-Jones, PhD4, Kim Harman, DHealth5, Alastair D. Hay, FRCGP6, on
behalf of the DUTY Study Team
1School of Social and Community Medicine, University of Bristol, Bristol, UK; 2Nufﬁeld Department of Primary Care Health Sciences,
University of Oxford, Oxford, UK; 3Division of Population Medicine, Cardiff University, Cardiff, UK; 4South East Wales Trials Unit
(SEWTU Centre for Trials Research), Cardiff University, Cardiff, UK; 5Primary Care and Population Sciences Division, University of
Southampton, Southampton, UK; 6Centre for Academic Primary Care, NIHR School of Primary Care Research, School of Social and
Community Medicine, University of Bristol, Bristol, UKA B S T R A C TObjective: To estimate the cost-effectiveness of a two-step clinical rule
using symptoms, signs and dipstick testing to guide the diagnosis and
antibiotic treatment of urinary tract infection (UTI) in acutely unwell
young children presenting to primary care.Methods: Decision analytic
model synthesising data from a multicentre, prospective cohort study
(DUTY) and the wider literature to estimate the short-term and lifetime
costs and healthcare outcomes (symptomatic days, recurrent UTI,
quality adjusted life years) of eight diagnostic strategies. We compared
GP clinical judgement with three strategies based on a ‘coefﬁcient
score’ combining seven symptoms and signs independently associated
with UTI and four strategies based on weighted scores according to the
presence/absence of ﬁve symptoms and signs. We compared dipstick
testing versus laboratory culture in children at intermediate risk of UTI.
Results: Sampling, culture and antibiotic costs were lowest in high-
speciﬁcity DUTY strategies (£1.22 and £1.08) compared to clinical
judgement (£1.99). These strategies also approximately halved urine
sampling (4.8% versus 9.1% in clinical judgement) without reducingee front matter Copyright & 2017, International S
r Inc. This is an open access article under the CC
1016/j.jval.2017.01.003
ollingworth@bristol.ac.uk.
ndence to: William Hollingworth, School of Social
ol BS8 2PS, UK.sensitivity (58.2% versus 56.4%). Outcomes were very similar across all
diagnostic strategies. High-speciﬁcity DUTY strategies were more cost-
effective than clinical judgement in the short- (iNMB = £0.78 and £0.84)
and long-term (iNMB =£2.31 and £2.50). Dipstick tests had poorer cost-
effectiveness than laboratory culture in children at intermediate risk of
UTI (iNMB = £-1.41). Conclusions: Compared to GPs’ clinical judge-
ment, high speciﬁcity clinical rules from the DUTY study could
substantially reduce urine sampling, achieving lower costs and equiv-
alent patient outcomes. Dipstick testing children for UTI is not cost-
effective.
Keywords: antibacterial agents, diagnosis, economics, medical,
pediatrics, urinary tract infections.
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Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Urinary tract infection (UTI) is the fourth most common reason for
prescribing antibiotics, accounting for approximately 8% of all anti-
bacterial prescriptions [1]. Appropriate diagnosis and treatment of
UTI in children presenting to primary care are particularly challeng-
ing because symptoms and signs are often nonspeciﬁc. The costs of
a urine sample, laboratory test, and antibiotic are relatively low [2].
The economic impact may, however, be substantial because of the
large number of acutely unwell children who present to primary
care, additional diagnostic tests for structural abnormalities of the
urinary tract [3], rare but serious complications of UTI, and the wider
impact of antibiotic prescribing on bacterial resistance [4].
The few economic evaluations of UTI diagnosis in children
[2,5,6] have compared the cost-effectiveness of urine tests oncea urine sample has been obtained. There is very limited
economic evidence to help primary care clinicians decide which
children should have a urine sample taken and whether dipstick
testing (DT) can guide therapy. Evidence is particularly needed
for young children for whom current clinical guidelines of the
National Institute for Health and Care Excellence [3] are not
based on strong evidence of cost-effectiveness. In the Diagnosis
of Urinary Tract infection in Young children (DUTY) study we
report the development of a two-step clinical rule and demon-
strate its superiority to routine clinical practice in the diagnosis
of UTI in acutely unwell young children presenting to primary
care in whom a clean catch urine sample was obtained. In this
article we estimate the cost-effectiveness of these two steps.
The ﬁrst step evaluates whether clinical rules based on signs
and symptoms identiﬁed in the DUTY study as predictive of UTIociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY license (http://creativecommons.org/licenses/by/4.0/).
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which children to test and treat for UTI. The second step
evaluates the additional value of DT once a urine sample has
been obtained.Methods
The DUTY Study
The DUTY study was a multicenter, prospective, diagnostic
cohort study that recruited children seeking care at National
Health Service (NHS) primary care sites in Bristol, Cardiff, London,
and Southampton. Children were eligible if younger than 5 years
and with complaints of any acute (o28 days) illness episode that
was associated with at least one potential marker for UTI [7].
Ethical approval was granted by the South West Southmead
Research Ethics Committee (ref. #09/ H0102/64).
Diagnostic Strategies
In the ﬁrst step, we compared a “clinical judgment” diagnostic
strategy with three strategies based on the DUTY “coefﬁcient
score” and four based on the simpler DUTY “points score.”
Clinical judgment was deﬁned by general practitioner (GP)
responses to questions on the DUTY case report form about
working diagnosis and planned management before urine sam-
pling. In the clinical judgment strategy, the proportion of lower
risk children was identiﬁed as those when the GP answered “No”
to the question “If this child was NOT in the DUTY study would
you have requested a urine sample?” or indicated a working
diagnosis of “Not UTI.” Higher risk children were those when the
GP had a working diagnosis of UTI and answered “Yes” to the
question “Before seeing the dipstick results, are you planning on
treating this child with antibiotics for suspected UTI?” Finally,
intermediate-risk children were those when the GP had a work-
ing diagnosis of UTI and the GP answered “Yes” to the question
“If this child was NOT in the DUTY study would you have
requested a urine sample?”
The DUTY coefﬁcient score is calculated from seven parent- or
clinician-reported symptoms and signs, weighted according to
the strength of independent association with UTI (see Appendix
Table 1 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2017.01.003). The simpler DUTY points score ranges
from 0 to 9 and is calculated from a subset of ﬁve symptoms and
signs that were dichotomized (e.g., present/absent) and assigned
an integer score (i.e., 1 or 2) representing the strength of
association with UTI (see Appendix Table 2 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2017.01.003).
The coefﬁcient-based score is more accurate than the points-
based score, but requires computational assistance to calculate.
The cut points for the DUTY diagnostic strategies (see Appendix
Table 3 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2017.01.003) were selected to represent a range from
more highly targeted (i.e., high speciﬁcity) to less highly targeted
(i.e., high sensitivity) urine sampling strategies.
In the second step, we compared the short-term cost-effective-
ness of immediate treatment on the basis of point-of-care DT versus
delayed treatment after laboratory testing (LT). Nitrites and leuko-
cytes (trace or more) were strongly and independently predictive of
UTI in the DUTY study [7]. We evaluated two DT strategies: 1)
immediate antibiotic if nitrite- or leukocyte-positive and 2) immedi-
ate antibiotic if nitrite- and leukocyte-positive.
Model Overview
The overall model comprises several submodels. First, a short-
term decision tree (Fig. 1) models testing and treatment duringthe index consultation. The acute illness phase is handled by a
nine-state Markov model (see Appendix Figure 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2017.01.003)
estimating the time taken to recover (maximum 21 days) on the
basis of the illness of the child and the treatment received.
Correct UTI diagnosis can also lead to early diagnosis of ves-
icoureteral reﬂux (VUR), an abnormality that allows urine to ﬂow
backward from the bladder into the kidneys. Children with VUR
are at increased risk of recurrent UTI (and subsequent pyelo-
nephritic attacks [PAs]), although this can be reduced through
prophylactic antibiotic treatment or surgery. Another Markov
model (see Appendix Figure 2 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2017.01.003) is used to calculate
the number of recurrent UTIs and PAs in the 3 years after the
index consultation. Finally, a long-term (lifetime) decision tree
(see Appendix Figure 3 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2017.01.003) models the impact of renal
scarring in the earlier phases on the model, which is an impor-
tant risk factor for long-term, potentially life-limiting renal
complications such as end-stage renal disease. In each submodel,
costs were estimated from a health service perspective and
outcomes were expressed using quality-adjusted life-years
(QALYs) or life-days (QALDs) [8].
Improved testing could lead to more targeted antibiotic treat-
ment and quicker symptom resolution during the initial infec-
tion, better preventative treatment in the medium term leading
to fewer renal scars (because of VUR treatment), and, conse-
quently, fewer long-term complications.Short-Term Decision Tree
The structure of the decision tree (Fig. 1) is identical for all eight
diagnostic strategies. Strategies differ in the proportion of chil-
dren classiﬁed as lower, intermediate, or higher risk of UTI. We
identiﬁed the proportion of children who are very unwell and
referred directly to hospital for testing and treatment (for both
UTI and non–UTI-related problems) as those when the GP
answered “Yes” to the question “Before seeing the dipstick
results, would you have referred this child to a pediatrician or
admitted this child to hospital?” A urine sample is requested in
children considered at higher risk of UTI and antibiotics pre-
scribed. If laboratory culture demonstrates bacteriuria resistant
to the prescribed antibiotic, the prescription will be changed. If no
UTI is found, the GP may contact the parent to stop treatment. If
the sample is contaminated, a repeat is sought. If no urine
sample is obtained in a higher risk child, symptoms are reviewed
in 2 days. If symptoms have not improved, the child is referred to
hospital.
Urine sampling is attempted in children classiﬁed as inter-
mediate risk of UTI, but antibiotic treatment is delayed until a
positive laboratory result is returned. Children who cannot
provide a sample are reviewed in 2 days and antibiotics are
prescribed only if symptoms have not resolved and the working
diagnosis is a (non-UTI) microbial infection. No urine sample is
requested in children classiﬁed as lower risk of UTI, although
antibiotics may be prescribed if the working diagnosis is a (non-
UTI) microbial infection. Therefore, children in whom a UTI is
undiagnosed may receive antibiotics serendipitously, although
higher rates of uropathogen resistance to nontargeted antibiotics
meant they often had slower symptom resolution than those
with correctly identiﬁed UTIs. Children with UTI may be referred
for ultrasound and, following a positive result, micturating
cystourethrogram to test for VUR [3]. We assumed that children
with a positive VUR diagnosis were treated with prophylactic
antibiotics according to National Institute for Health and Care
Excellence guidelines [3].
Fig. 1 – Decision tree for diagnosis and initial treatment of UTI
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used to determine the initial treatment of children considered to be
at intermediate risk of UTI on the basis of symptoms and signs(Fig. 1). Children with a positive dipstick result are prescribed anti-
biotics immediately, whereas no antibiotic is initiated until labora-
tory culture results are known in those with negative dipstick results.
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Recovery in the 21 days after the initial consultation is modeled
using a nine-state Markov process with a single-day cycle length
(see Appendix Figure 1 in Supplemental Materials). Each health
state has a cost and a utility score. The transition probabilities
vary by state depending on the child’s health status (e.g., whether
pyelonephritis is present) and treatment prescribed. For example,
UTI promptly diagnosed and treated with an antibiotic will
become asymptomatic more rapidly than undiagnosed and
untreated UTI.
Medium- and Long-Term Models
The medium-term model (see Appendix Figure 2 in Supplemental
Materials) estimates the number of recurrent UTIs and PAs, with
the associated costs and disutility, in the 3 years after the index
consultation. We made the simplifying assumptions that chil-
dren present with symptoms or signs potentially indicative of
UTI at most annually and hence our cycle length was 1 year.
Children with untreated VUR or previous UTI were at increased
risk of recurrent UTI and PAs; these risks were, however, constant
across all years of the medium-term model and were not affected
by antibiotic treatment received during the index consultation.
Costs and utilities of repeat presentations are identical to the
index consultation and therefore dependent on the diagnostic
strategy adopted. The long-term model (see Appendix Figure 3 in
Supplemental Materials), which is based on previous work [2],
calculates the lifetime cost, quality of life, and mortality con-
sequences of the most severe UTI complications (progressive
renal scarring [PRS] and end-stage renal disease [ESRD]). The
probability of these complications increases with the number of
PAs in the short- and medium-term phases of the model.
Risk Stratiﬁcation
Of the 3036 children in the DUTY providing a clean catch urine
sample, we excluded those with a missing or contaminated
research laboratory result (n ¼ 346; 11.4%), dipstick result (n ¼ 8;
0.3%), or information on GP clinical judgment (n ¼ 6; 0.2%).
Microbiologically conﬁrmed UTI was deﬁned as 105 CFUs/mlTable 1 – Risk stratiﬁcation for clinical judgment and DU
Diagnostic strategy Actual UTI status
Lower
Clinical judgment No UTI (%) 2276 (91.48)
UTI (%) 24 (43.64)
DUTY5% No UTI (%) 2393 (96.18)
UTI (%) 23 (41.82)
DUTY10% No UTI (%) 2271 (91.28)
UTI (%) 16 (29.09)
DUTY20% No UTI (%) 2004 (80.55)
UTI (%) 8 (14.55)
DUTYZ6 No UTI (%) 2395 (96.26)
UTI (%) 31 (56.36)
DUTYZ5 No UTI (%) 2340 (94.05)
UTI (%) 26 (47.27)
DUTYZ4 No UTI (%) 1946 (78.22)
UTI (%) 11 (20.00)
DUTYZ3 No UTI (%) 1829 (73.51)
UTI (%) 8 (14.55)
DUTY, Diagnosis of Urinary Tract infection in Young children; UTI, urin
* Excludes patients who did not have UTI results, those referred imm
calculation of clinical judgment decision.(CFU, colony-forming unit) or more of a single or predominant
uropathogen in the research laboratory culture. Contamination
was deﬁned as an NHS laboratory report of heavy mixed growth
greater than 105 CFUs/ml of more than two organisms [9].
In all strategies, 5% (133 of 2676) of children, including 5 with
UTI, were reported by the GP to be “very unwell” and assumed to
be referred to hospital for treatment. On the basis of clinical
judgment, most of the remaining children (2276 of 2488; 91%)
who did not have UTI were classiﬁed as lower risk, but only 56%
(31 of 55) of children with UTI were classiﬁed as intermediate or
higher risk (Table 1). When using the DUTY score, the DUTY5%
and DUTYZ6 strategies had the highest speciﬁcity, whereas the
DUTY20% and DUTYZ3 strategies had the highest sensitivity.
Short-Term Model Parameters
In the DUTY study, 60 (2.2%) of 2676 children with an uncon-
taminated clean catch urine sample had a research laboratory–
conﬁrmed UTI (Table 2). Nine (16.3%) of 55 children with con-
ﬁrmed UTI and temperature recorded had fever (4381C) and were
assumed to have PA. The prevalence of VUR among children with
UTI was estimated from a previous meta-analysis [10].
UTI resistance to non-UTI and UTI antibiotics was based on
observed resistance (amoxicillin and trimethoprim, respectively) in
the DUTY research laboratory reports. We estimated the proportion
of children for whom an antibiotic was prescribed for another
disease (not UTI) by calculating the proportion of children without
UTI in DUTY whose parents reported antibiotic use within 2 days of
the initial consultation. We assumed that 19% of children would
return to primary care before symptom resolution [11], whereas the
probability of further investigation of VUR was based on the
proportion of DUTY children with UTI who had an ultrasound scan
within 3months. The estimates of the diagnostic accuracy of dipstick
tests and NHS laboratory results were deﬁned against the research
laboratory in the DUTY study. Estimates of the diagnostic accuracy of
ultrasound scans were taken from a previous meta-analysis [2].
Symptom Resolution
Daily symptom resolution data were collected from parents in DUTY
for 14 days after the consultation and used to estimate symptomTY clinical rules*.
Risk strata
Intermediate Higher Multinomial distribution
83 (3.34) 129 (5.18) (2276, 83, 129)
9 (16.36) 22 (40.00) (24, 9, 22)
52 (2.09) 43 (1.73) (2393, 52, 43)
12 (21.82) 20 (36.36) (23, 12, 20)
122 (4.90) 95 (3.82) (2271, 122, 95)
7 (12.73) 32 (58.18) (16, 7, 32)
267 (10.73) 217 (8.72) (2004, 267, 217)
8 (14.55) 39 (70.91) (8, 8, 39)
82 (3.30) 11 (0.44) (2395, 82, 11)
17 (30.91) 7 (12.73) (31, 17, 7)
55 (2.21) 93 (3.74) (2340, 55, 93)
5 (9.09) 24 (43.64) (26, 5, 24)
394 (15.84) 148 (5.95) (1946, 394, 148)
15 (27.27) 29 (52.73) (11, 15, 29)
511 (20.54) 148 (5.95) (1829, 511, 148)
18 (32.73) 29 (52.73) (8, 18, 29)
ary tract infection.
ediately to secondary care, or when missing data did not allow
Table 2 – Parameters used to estimate diagnosis and treatment pathways and health status.
Parameter Estimate Distribution Source
Short-term model
UTI prevalence 0.022 Binomial (60, 2676) DUTY
PA (among those with UTI) 0.164 Binomial (9, 55) DUTY
VUR (among those with UTI) 0.240 OddsLN* (1.153, 0.113) [10]
Very unwell† 0.050 Binomial (133, 2676) DUTY
Urine sample obtained‡ 0.957 Binomial (2231, 2332) DUTY
Contamination 0.046 Binomial (140, 2619) DUTY
Antibiotic resistance (amoxicillin) 0.531 Binomial (50, 94) DUTY
Antibiotic resistance (trimethoprim) 0.277 Binomial (26, 94) DUTY
Reconsultation 0.189 Binomial (42, 222) [11]
Antibiotics for non-UTI reason 0.294 Binomial (78, 262) DUTY
Stop antibiotic given no UTI 0.075 Uniform (0.05, 0.10) Expert opinion
Referred for US 0.059 Binomial (6, 103) DUTY
Dipstick (L or N) DUTY
Sensitivity 0.767 Binomial (46, 60)
Speciﬁcity 0.841 Binomial (2200, 2616) DUTY
Dipstick (L and N) DUTY
Sensitivity 0.367 Binomial (22, 60)
Speciﬁcity 0.989 Binomial (2588, 2616) DUTY
Laboratory test§ DUTY
Sensitivity 0.789 Binomial (45, 57)
Speciﬁcity 0.976 Binomial (2341, 2398) DUTY
US for VUR [2]
Sensitivity 0.440 OddsLN (0.243, 0.2352)
Speciﬁcity 0.775 OddsLN (1.238, 0.2862) [2]
MCUG for VUR 1.000 Fixed Assumption
Sensitivity
Speciﬁcity 1.000 Fixed Assumption
Antibiotic treatment effect|| 0.550 RRLN (0.599, 0.247) [12]
Reduced effect in resistant bacteria 0.700 Uniform (0.5, 0.9) Expert opinion
Medium-term model
Consult—no UTI 0.693 Binomial (21193, 30588) [29]
Consult—UTI, no history¶ 0.003 Binomial (9.33, 2789) [30]
Consult—UTI, history, and no/treated VUR 0.080 OddsLN (2.442, 0.2182) [10]
Treatment effect for treated VUR# 0.68 RRLN (0.385, 0.2802) [31]
Long-term model
PRS [25]
0 PA 0.050 Binomial (7, 141)
1 PA 0.087 Binomial (32, 366)
2 PA 0.161 Binomial (15, 93)
3 PA 0.343 Binomial (12, 35)
4 PA 0.583 Binomial (14, 24)
ESRD given PRS 0.050 [32]
Mean age of ESRD onset 13.67 Triangle (7, 24) [33,34]
Transplant 0.500 Assumption
Dialysis 0.500 Assumption
Years survival—no ESRD 73.00 Uniform (69.4, 76.7) [35]
Years survival—dialysis 12.25 Uniform (11.6, 12.9) [36]
Years survival—transplant 21.60 Uniform (20.5, 22.7) [37]
ESRD, end-stage renal disease; GP, general practitioner; MCUG, micturating cystourethrogram; L, leukocytes; N, nitrates; NHS, National Health
Service; PA, pyelonephritic attack; PRS, progressive renal scarring; US, ultrasound; UTI, urinary tract prevalence; VUR, vesicoureteral reﬂux.
* Lognormal.
† GP answered “Yes” to the question “Before seeing the dipstick results, would you have referred this child to a pediatrician or admitted this
child to hospital.”
‡ On the basis of the proportion of children older than 3 y for whom a sample was obtained.
§ After removing samples that were found to be contaminated in the NHS laboratory.
|| Risk ratio comparing symptom resolution rates for children not treated with antibiotics to those in children treated with antibiotics.
¶ Numerator adjusted to account for 18-mo follow-up period.
# Relative risk comparing UTI recurrence rates in children with VUR with children without VUR.
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(see Appendix Figure 4 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2017.01.003). We extrapolated these results to 21
days using Weibull survival models because symptoms had not
resolved by 14 days for some children. We estimated the symptom
resolution rate in children with untreated UTI on the basis of a small
randomized controlled trial comparing nitrofurantoin to placebo in
women with bacteriologically proven UTI (Table 2) [12]. We assumed
that symptom resolution was reduced by 30% when uropathogens
were resistant to the prescribed antibiotic.
For children with delayed antibiotic treatment (e.g., waiting
for a laboratory test result), we assumed that daily symptom
resolution probabilities were the same as untreated UTI for the
ﬁrst 2 days. We assumed that the antibiotic treatment effect
persisted for 7 days, meaning treated and untreated symptom
resolution probabilities were identical between day 8 and day 21,
and that all symptoms resolved by 21 days.
Medium- and Long-Term Model Parameters
Estimates of the probability of primary care reconsultation
with or without UTI, effectiveness of prophylactic treatment in
children with VUR, long-term incidence of PRS and ESRD, and
survival are presented in Table 2 and detailed elsewhere [9].
Costs and Utilities
On the basis of observations in the DUTY study, the average time
taken for a urine sample with and without a dipstick test was 12.0
minutes (cost £8.10) and 9.1 minutes (cost £7.03), respectively (see
Appendix Table 4 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2017.01.003). We assumed that GPs spent 45
seconds (cost £2.42) interpreting laboratory results and 5 minutes
(cost £16.08) contacting parents to revise prescriptions. We
estimated antibiotic costs on the basis of amoxicillin (125 mg/
5 ml) for children treated for a non-UTI diagnosis and trimetho-
prim (50 mg/5 ml) for children with a UTI diagnosis. Other costs
of initial care were based on a questionnaire completed by
parents in the DUTY study 14 days postconsultation. We mapped
drugs to British National Formulary codes [13] using the 2011
prescription cost analysis data set [14]. In the longer term we
assumed that children with PRS have no increased costs of care
until the onset of ESRD. Individuals with ESRD are treated by
dialysis with an ongoing annual cost until death [15] or renal
transplant with a treatment cost at the time of the procedure. All
costs were inﬂated to 2014/2015 prices using the hospital and
community health services pay and prices inﬂation factor [16].
In the absence of utility studies in infants with UTI [17], we
used estimates from a study on rotavirus [18] (see Appendix
Table 4 in Supplemental Materials) because the Preschool Chil-
dren Quality Of Life (TAPQOL) questionnaire, administered to
children in the DUTY study, demonstrated that health-related
quality of life for children with UTI and gastroenteritis was
similar (see Appendix Table 5 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2017.01.003). We used utility
values for pyelonephritis in adults reported in the literature
[19]. We assumed that individuals with PRS experience no
quality-of-life decrement until ESRD onset. Utility estimates for
patients on dialysis and after renal transplant were estimated
from previous research [20].
Analysis
Data management was conducted in STATA (StataCorp,
College Station, TX) and the model was implemented in Winbugs
1.4.3 (MRC biostatistics unit, Cambridge, UK) [21] using
diffuse prior distributions for all parameters. The full model
code is available in File 1 in Supplemental Materials found athttp://dx.doi.org/10.1016/j.jval.2017.01.003. We calculated the
expected costs, beneﬁts, and incremental net monetary beneﬁt
(iNMB) [22] of each strategy compared with clinical judgment
assuming the health service is willing to pay £20,000/QALY [23].
Outcomes and costs beyond the ﬁrst year were discounted at
3.5% [23]. We assigned probability distributions to each model
parameter and used Markov chain Monte-Carlo sampling to
propagate parameter uncertainty through to the outcomes.
We undertook the following deterministic sensitivity analyses
to evaluate the robustness of our conclusions to model assump-
tions: 1) increase in UTI prevalence to 10%; 2) perfectly accurate
NHS laboratory cultures; 3) doubled antibiotic treatment effect; 4)
doubled disutility from UTI infection; 5) simpler model excluding
VUR and pyelonephritis; 6) doubled probability of PRS; and 7)
doubled cost of ESRD.Results
Diagnostic Accuracy and Treatment
The DUTY study GPs reported a working diagnosis of UTI in 9.1%
of children when using clinical judgment including just over half
of children who had a conﬁrmed UTI (sensitivity ¼ 56.4%;
Table 3). Using the DUTY5% strategy, urine sampling could be
approximately halved (4.8%) without any loss of sensitivity
(58.2%). Alternatively, the DUTY10% strategy samples a similar
proportion (9.6%) of children as clinical judgment, but has sub-
stantially higher sensitivity (70.9%). The most sensitive DUTY
clinical rules (DUTY20% and DUTYZ3) achieved sensitivities in
excess of 80%, but resulted in large increases in urine sampling
(19.9% and 26.4%, respectively). The sensitivity of each strategy is
reduced by the laboratory culture because NHS laboratories had
imperfect diagnostic accuracy. Compared with clinical judgment,
the DUTY10% rule results in a higher proportion of children with
UTI treated with an antibiotic to which the bacterium was
sensitive (56.4% vs. 49.2%). Nevertheless, a substantial proportion
(434%) of children with UTI receive either no or an inappropriate
antibiotic under all strategies.Short-Term Costs and Outcomes
Mean sampling, laboratory culture, and antibiotic costs were the
lowest in the high-speciﬁcity diagnostic strategies (e.g., DUTYZ6
£1.08; DUTY5% £1.22; and clinical judgment £1.99; Table 3). Short-
term outcomes were very similar between diagnostic strategies.
Short-term average QALDs were 20.73 for all strategies, whereas
the number of asymptotic days ranged from 16.34 to 16.35,
although small differences existed at the third and fourth
decimal places. These similarities are driven by the low preva-
lence of UTI, the small differences in diagnostic accuracy of
strategies, and the limited effect of antibiotics on acute symptom
duration.
The high-speciﬁcity DUTY clinical rules (DUTY5%, DUTYZ6,
and DUTYZ5) were more cost-effective than clinical judgment in
the short-term (iNMB ¼ £0.78, £0.84, and £0.42, respectively;
Table 3). These efﬁciencies are predominantly due to ﬁnancial
savings arising from fewer, better targeted, urine samples com-
pared with clinical judgment. The DUTY10% rule had similar
short-term cost-effectiveness to clinical judgment (iNMB ¼ £0.00).
For the highest sensitivity DUTY clinical rules (DUTY20%,
DUTYZ4, and DUTYZ3), the beneﬁt of identifying and treating
slightly more UTIs was outweighed by the higher costs of
sampling and testing substantial numbers of children (iNMB ¼
£1.69, £1.93, £2.61, respectively).
Table 3 – Short-term costs and beneﬁts of seven DUTY diagnostic strategies compared with clinical judgment.
Costs and outcomes Clinical
judgment
DUTY5% DUTY10% DUTY20% DUTYZ6 DUTYZ5 DUTYZ4 DUTYZ3
Diagnostic pathway
Urine sample requested (%) 9.12 4.79 9.61 19.89 4.40 6.65 21.94 26.43
Sensitivity—urine sampling 0.564 0.582 0.709 0.854 0.436 0.527 0.800 0.854
Speciﬁcity—urine sampling 0.915 0.962 0.913 0.805 0.963 0.941 0.782 0.735
Sensitivity—after laboratory test* 0.426 0.439 0.536 0.645 0.330 0.398 0.604 0.645
Speciﬁcity—after laboratory test† 0.998 0.999 0.998 0.996 0.999 0.999 0.995 0.994
Treatment pathway (children with
UTI)
Immediate, appropriate‡ antibiotic (%) 36.64 34.05 46.48 52.80 20.67 39.48 41.75 41.03
Laboratory informed§, appropriate
antibiotic (%)
12.51 16.55 9.94 11.40 23.14 7.12 20.74 24.81
Inappropriate antibiotic (%) 17.56 16.50 20.01 21.22 12.79 18.83 17.68 17.03
No antibiotic (%) 33.29 32.90 23.56 14.59 43.40 34.58 19.83 17.14
Treatment pathway (children without
UTI)
Antibiotic treatment for UTI (%) 4.79 1.62 3.56 8.16 0.47 3.45 5.75 5.85
Short-term costs and outcomes
Costs per child
Sampling, culture, antibiotic
treatment costs
1.99 1.22 2.05 3.80 1.08 1.57 3.99 4.68
Initial (21 d) health service costs 44.06 43.28 44.07 45.78 43.19 43.63 46.01 46.69
Outcomes
Asymptomatic days 16.34 16.34 16.35 16.35 16.34 16.34 16.35 16.35
Short-term average QALDs 20.73 20.73 20.73 20.73 20.73 20.73 20.73 20.73
Cost-effectiveness
iNMB|| per child (95% CI) – 0.78 (0.76 to
0.79)
0.00 (0.00 to
0.01)
1.69 (1.71 to
1.68)
0.84 (0.83 to
0.85)
0.42 (0.41 to
0.43)
1.93 (1.95 to
1.92)
2.61 (2.63 to
2.59)
CI, conﬁdence interval; DUTY, Diagnosis of Urinary Tract infection in Young children; iNMB, incremental net monetary beneﬁt; QALDs, quality-adjusted life-days; UTI, urinary tract infection.
* The proportion of children with UTI whose urine is sampled and the laboratory culture is positive.
† The proportion of children without UTI whose urine is not sampled or the laboratory culture is negative.
‡ (In)appropriate deﬁned as an antibiotic to which the bacterium is (not) sensitive.
§ Antibiotic prescribing determined by laboratory result, usually started a few days after primary care attendance.
|| On the basis of a £20,000/QALY threshold; compared with clinical judgment strategy (bootstrapped 95th percentile CI); a positive value indicates that the strategy is more cost-effective than
clinical judgment.
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Table 4 – Medium- and long-term costs and beneﬁts of seven DUTY diagnostic strategies compared with
clinical judgment.
Costs and
outcomes
Clinical
judgment
DUTY5% DUTY10% DUTY20% DUTYZ6 DUTYZ5 DUTYZ4 DUTYZ3
Average
number of
UTI
recurrence at
3 y/10,000
patients
165.5 165.5 165.5 165.4 165.5 165.5 165.5 165.4
% ESRD* 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250
Average years
lived
72.94 72.94 72.94 72.94 72.94 72.94 72.94 72.94
Average lifetime
cost
182.3 179.9 182.2 187.3 179.7 181.0 188.1 190.1
Average lifetime
QALY
25.74 25.74 25.74 25.74 25.74 25.74 25.74 25.74
iNMB†, per child
(95% CI)
– 2.31 (2.30
to 2.33)
0.00 (0.01
to 0.01)
5.00
(5.03 to
4.97)
2.50 (2.49
to 2.51)
1.22 (1.21
to 1.23)
5.78
(5.81 to
5.75)
7.78
(7.82 to
7.74)
iNMB, annual
UK‡
– £10.75M £0.00M £23.25M £11.63M £5.67M £25.88M £36.18M
CI, conﬁdence interval; ESRD, end-stage renal disease; iNMB, incremental net monetary beneﬁt; QALY, quality-adjusted life-year; UTI: urinary
tract infection.
* Strategies are estimated to have no impact on lifetime ESRD or QALYs to three decimal places because most children do not have UTI, most
children with UTI will not develop ESRD, each strategy has only a small impact on the proportion of children with UTI treated
inappropriately, and the effect of prophylaxis on ESRD incidence is uncertain.
† On the basis of a £20,000/QALY threshold; compared with clinical judgment strategy (bootstrapped 95th percentile CI); a positive value
indicates that the strategy is more cost-effective than clinical judgment.
‡ Assuming one consultation per annum with acute illness when a clean catch sample could be collected for each of UK’s 4.65 million children
younger than 5 y.
Table 5 – Costs and beneﬁts of DT compared with LT in children judged to be intermediate risk for UTI.
Costs and outcomes DUTY5%
LT DT (L or N) DT (L and N)
Diagnostic pathway
Dipstick test (%) 0.00 95.67 95.67
Treatment pathway (children with UTI)
Immediate, appropriate antibiotic (%) 0.00 52.22 24.98
Treatment determined by laboratory culture, appropriate antibiotic (%) 78.45 18.39 49.73
Inappropriate antibiotic (%) 3.32 22.00 12.25
No antibiotic (%) 18.23 7.39 13.05
Treatment pathway (children without UTI)
Antibiotic treatment for UTI (%) 2.27 17.13 3.27
Short-term costs and outcomes
Costs per patient
Sampling, dipstick, culture, and antibiotic treatment 15.66 17.70 17.13
Total short-term cost 57.71 59.66 59.14
Outcomes
Asymptomatic days 16.34 16.35 16.35
Short-term average QALDs 20.73 20.73 20.73
Summary measure
iNMB, per child (95% CI)* – 1.91 (1.99 to 1.83) 1.41 (1.50 to 1.32)
CI, conﬁdence interval; DT, dipstick-based treatment; DUTY, Diagnosis of Urinary Tract infection in Young children; iNMB, incremental net
monetary beneﬁt; L, leukocytes; LT, laboratory-based treatment; N, nitrates; QALDs, quality-adjusted life-days; QALY, quality-adjusted life-
year; UTI, urinary tract infection.
* On the basis of a £20,000/QALY threshold; compared with clinical judgment strategy (bootstrapped 95th percentile CI); a positive value
indicates that the strategy is more cost-effective than clinical judgment.
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In the medium and long-term, diagnostic strategies with the
highest sensitivity led to VUR treatment in a larger proportion of
cases and had slightly lower rates of UTI recurrence (Table 4).
Nevertheless, differences between strategies in life expectancy
and QALYs were negligible. The high-speciﬁcity diagnostic strat-
egies (i.e., DUTY5%, DUTYZ6, and DUTYZ5) were more cost-
effective than clinical judgment in the long-term (iNMBs £2.31,
£2.50, and £1.22, respectively). Even small differences in net
beneﬁts per child are important given the large number of children
with acute illness presenting to primary care (Table 4, ﬁnal row).
Laboratory versus Dipstick-Based Treatment
In the DUTY5% strategy, 2.3% of children (18.8% of whom have
UTI) are considered intermediate risk (Table 1) and, in the
absence of a dipstick test, clinicians would have delayed treat-
ment pending the laboratory test result. DT and treatment for
children with positive leukocytes and nitrites result in 25.0% of
those with intermediate risk of UTI receiving immediate anti-
biotics to which the bacterium was sensitive (Table 5). Never-
theless, DT increased the proportion of children without UTI
incorrectly treated compared with LT (3.3% vs. 2.3%). Average
sampling, testing, and treatment costs are higher in this DT
strategy (£17.13) than in the LT strategy (£15.66), mainly because
of the additional time and cost of the dipstick test. Both DT
strategies had poorer cost-effectiveness compared with those
based on LT of children at intermediate risk of UTI (iNMB ¼
£1.41 for leukocytes and nitrites; iNMB ¼ £1.91 for leukocytes
or nitrites).
Sensitivity Analysis
Both the probabilistic (Tables 3 and 4) and deterministic sensitivity
analyses (see Appendix Tables 6 and 7 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2017.01.003) indicate that
the ﬁnding that the DUTY5% strategy is more cost-effective than
clinical judgment is robust to substantial changes in key model
parameters. Our short-term results were similar when using a
simpliﬁed model that did not seek to estimate the impact of VUR
or pyelonephritis, suggesting that these elements did not play an
important role in driving our conclusions.Discussion
Summary of Findings
We evaluated the cost-effectiveness of a two-step clinical rule
using symptoms, signs, and dipstick test results to select children
for urine sampling and antibiotic treatment. Compared with GPs’
clinical judgment, the DUTY5% clinical rule could substantially
reduce urine sampling, achieving lower costs and equivalent
patient outcomes. DUTY points-based rules are more cost-
effective than clinical judgment at high-speciﬁcity thresholds
(DUTYZ5 and DUTYZ6) and could be used when it is infeasible
to estimate the DUTY coefﬁcient-based score. Our ﬁndings
suggest that urine sampling should be more carefully targeted,
rather than increased, but do not support the use of DT in
children at intermediate risk of UTI. The beneﬁts of immediate
dipstick-guided treatment were counterbalanced by imperfect
test speciﬁcity resulting in more antibiotic prescriptions in
children without UTI.
Strengths and Limitations
Our model was based on individual patient data from a large,
rigorously conducted, prospective diagnostic cohort study.Therefore, most of the parameters underlying the short-term
model come from a consistent, high-quality data source. In the
DUTY study, urine samples were analyzed by both health service
and research laboratories providing more accurate estimates of
the prevalence of UTI and contamination. Furthermore, we were
able to model the impact of false-negative laboratory results and
antibiotic resistance on the efﬁciency of UTI diagnosis. Our
results are based on evidence from children for whom clean
catch samples were collected and are not necessarily general-
izable to younger children for whom nappy pads are generally
used for sampling. The clinical judgment diagnostic strategy
aimed to represent current practice, on the basis of clinicians’
responses to questions about working diagnoses and testing and
treatment plans. DUTY study participation may have, however,
sensitized clinicians to the possibility of UTI, leading to an
overestimate of urine sampling rates. Although this would not
alter our conclusion that selected symptoms and signs can help
primary care clinicians to target urine sampling, it does
strengthen the interpretation that high-speciﬁcity diagnostic
strategies (e.g., DUTY5% and DUTYZ5) are most likely to be
cost-effective in diagnosing and treating UTI.
Some of the evidence underlying the model was imprecise
and potentially biased. For example, there is no randomized
controlled trial–based evidence on the effect of antibiotics in
young children with UTI. The evidence underlying the long-term
model is based on observational associations between recurrent
UTI and renal disease, which continues to evolve: the Random-
ized Intervention for Children with Vesicoureteral Reﬂux (RIVUR)
trial comparing daily trimethoprim-sulfamethoxazole prophy-
laxis to placebo in children with VUR recently reported a 50%
reduction in recurrent UTI, but no trend for reduced incidence of
renal scarring [24]. Similarly, the choice of sampling distribution
for some parameters, in particular costs and utilities, was based
on convention rather than on primary data, introducing subjec-
tivity into the probabilistic sensitivity analysis.
Our model did not include other potential long-term conse-
quences of UTI such as pregnancy-related complications or
hypertension in which the causal role of UTI is debated and
difﬁcult to ascertain [25,26]. It is possible that other long-term
consequences of UTI exist. Identifying and including these would
favor more sensitive strategies. Nevertheless, our conclusions
were insensitive to different assumptions about the long-term
sequelae of UTI. The model results are dominated by the short-
term costs of testing and treating rather than by the long-term
sequelae because most children presenting to primary care do
not have UTI, most children with UTI will not develop ESRD, and
each strategy has only a small impact on the proportion of
children treated appropriately.
The large number of risk thresholds and the multiple ways of
using DT and laboratory culture to guide treatment produce an
almost unlimited number of potential management strategies.
We evaluated some that closely reﬂect current practice, but other
unevaluated strategies could prove more cost-effective. We did
not quantify the societal costs of antibiotic resistance. Current
methods may underestimate the cost of antibiotic resistance, and
accurate estimation may not be possible [4]. Given increasing
levels of resistance and the paucity of new antibiotics, the
inclusion of these costs would further strengthen the case for
high-speciﬁcity diagnostic strategies that limit prescriptions to
those most likely to have a UTI.
Results in Context with Other Studies
As far as we are aware, this is the ﬁrst study to evaluate the cost-
effectiveness of a clinical rule to identify children with UTI in
primary care. Previous work has assessed the most cost-effective
test or series of tests for diagnosing UTI rather than evaluating
V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 5 5 6 – 5 6 6 565which children should be considered at risk of UTI. An economic
model evaluating testing strategies for children with suspected
UTI concluded that either presumptive treatment or treatment
based on positive dipstick nitrites and leukocytes and micturat-
ing cystourethrogram was optimal [2]. Our ﬁndings suggest that
waiting for a positive laboratory culture is more cost-effective in
children at intermediate risk of UTI. The differences in ﬁndings
are likely to be partly due to the inclusion of serendipitous
treatment and detailed daily symptom resolution rates in
our model.Clinical and Research Implications
Each year large numbers of young children present to primary
care with acute illness. Therefore, even small modiﬁcations to
diagnostic strategies for common conditions such as UTI will
have a large impact on aggregate costs and workload. Our
ﬁndings demonstrate the need for clinicians to base the decision
to collect a urine sample on symptoms and signs known to be
predictive of UTI in primary care rather than on personal judg-
ment or on evidence derived from secondary care. Our results
also illustrate the trade-off between the small but certain short-
term costs of UTI diagnosis and treatment against the important
but less certain beneﬁts of detecting and treating UTI and
potentially preventing renal disease.
Our ﬁndings suggest that clinicians should select low-cost,
high-speciﬁcity diagnostic strategies. A GP requesting urine
samples in children by using the DUTY5% strategy would sample
4.8% of all acutely unwell children and request a sample in 58% of
children who have UTI at a testing and antibiotic cost of £1.22 per
child. In settings where symptoms and signs are routinely
recorded in electronic records, this process could be automated.
Nevertheless, in settings where resources do not permit this, a GP
using the DUTYZ5 strategy would sample 6.7% of all acutely
unwell children, including 53% of children who have UTI, at a
testing and antibiotic cost of £1.57 per child. Both strategies are
more cost-effective than clinical judgment alone.
Our research does not support the routine use of DT to guide
treatment. This conclusion is, however, based on weak evidence
about the effect of antibiotics. Trial evidence comparing the
cost-effectiveness of management strategies in women with
suspected UTI concluded that all strategies achieved similar
symptom control and that dipstick test–guided management
was likely, albeit with considerable uncertainty, to be cost-
effective [27,28]. A similar trial of management strategies in
infants is needed. Studies of parent-reported quality of life and
disutility of UTI symptoms in young children would enable more
precise estimates of short-term beneﬁts of antibiotics. Long-term
epidemiological study designs are needed to better quantify and
understand the association between childhood UTI and renal
disease.Conclusions
The DUTY study coefﬁcient and point scores were more cost-
effective than GPs’ clinical judgment in selecting children for
urine sampling and treatment for UTI. Small differences between
strategies in cost-effectiveness are important given the large
number of urine samples collected in children. High-speciﬁcity
thresholds, such as DUTYZ5, are simple to implement and likely
to be most cost-effective than clinical judgment. Our ﬁndings do
not support the routine use of DT, but trial evidence is needed
to compare the cost-effectiveness of various management
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